Our Services
Core Team
Consulting Network
Resources
- Case Studies
- Blog
- News
- Whitepapers
Careers
Contact

Blog

news and resources
Blog

All
Product Development
Business Development
Clinical Development
Strategy & Commercialization
Valuations
Regulatory Affairs
Opportunity Mapping
Research & IP evaluation
Business Strategy
Cell Therapy
Clinical Development Strategy
Due Diligence
Fibrosis
Interim Chief Medical Officer
Microbiome
New Product Planning
Oncology
Partnering
Partnering & deal-making
Pharma Licensing
Technology Transfer

Peter G Traber

Recent Posts

Summer in Paris: NASH Update

Title: Summer in Paris: NASH Update Author: Peter G. Traber, MD Date: 07/16/2019 The Paris NASH meeting was held July 11 and 12, 2019, subtitled as an “International Think Tank” and it certainly did...

No Acceptable Surrogates for NASH Cirrhosis

Title: No Acceptable Surrogates for NASH Cirrhosis Author: Peter G. Traber, MD Date: 06/06/2019 The FDA released draft guidance on developing drugs for compensated NASH cirrhosis (Nonalcoholic...

Therapy for NASH Cirrhosis is a Distant Hope

NASH is a chronic liver disorder that results in progressive fibrosis, ultimately culminating in some patients in liver cirrhosis. In cirrhosis, the fibrotic scar tissue distorts the normal liver...

Is Gilead’s Selonsertib for NASH Dead?

Title: Is Gilead’s Selonsertib for NASH Dead? Author: Peter G. Traber, MD Date: 02/12/2019 Introduction The search for an effective therapy for NASH with advanced fibrosis/cirrhosis suffered a major...

NASH Surprises and Interpretation of Clinical Trials

Title: NASH Surprises and Interpretation of Clinical Trials Author: Peter G. Traber, MD Introduction 2019 will usher in a new chapter in NASH drug development with data reported on the first phase 3...

Agencies Clarify NASH Endpoints—But Don’t Harmonize

Title: Agencies Clarify NASH Endpoints—But Don’t Harmonize Author: Peter G. Traber, MD The FDA and EMA have recently published very similar clinical trial endpoints for pre-cirrhotic NASH, with one...

Industry Strategies for NASH Combination Therapies

Introduction: Many have commented that drug combinations represent the future of NASH therapeutics. As indicated by Pfizer’s recent announcement, large pharma companies are putting efforts toward the...

Is Rapid Reversal of Liver Fibrosis Possible?

Title: Is Rapid Reversal of Liver Fibrosis Possible? Author: Peter G. Traber Introduction Treatment of liver fibrosis is a major focus of drug development with multiple companies examining a variety...

NASH Cirrhosis Space Poised to Heat Up

Title: NASH Cirrhosis Space Poised to Heat Up Author: Peter G. Traber, MD NASH cirrhosis is the most advanced classification of fibrosis progression in fatty liver disease. Results of clinical trials...

Madrigal’s and Viking’s NASH Drugs: Who’s best in class?

Title: Madrigal’s and Viking’s NASH Drugs: Who’s best in class? Author: Peter G. Traber, MD Two companies, Madrigal Pharmaceuticals (NASDAQ: MDGL) and Viking Therapeutics (NASDAQ: VKTX), this year...

NASH Bubble?

Title: NASH Bubble? Author: Peter G. Traber, MD Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) have been the subject of intense interest in the biotech/pharma...

Identifying Best Disease Indications for Anti-Fibrotic Drugs

Identifying Best Disease Indications for Anti-Fibrotic Drugs By Peter G. Traber, MD

1

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

Strategy and Commercialization Learn more
Product Development Learn more
Business Development Learn more

© 2009-24 Alacrita Holdings Limited | Pharma & Biotech Consulting

Privacy Notice

Alacrita Consulting
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608

One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.